STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 6th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Stock Purchase Agreement (“Agreement”) is entered into as of February 14, 2021 (the “Execution Date”), by and between Glaxo Group Limited, a private limited liability company incorporated under the laws of England and Wales having an office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”), and Vir Biotechnology, Inc. a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Vir”). The capitalized terms used herein and not otherwise defined have the meanings given to them in Appendix 1.
Preliminary Collaboration AgreementPreliminary Collaboration Agreement • May 6th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Preliminary Collaboration Agreement (this “Preliminary Collaboration Agreement” or “PCA”) is entered into as of February 14, 2021 (the “PCA Execution Date”), by and between Glaxo Wellcome UK Limited, (“GSK”) and Vir Biotechnology, Inc. (“VIR”). VIR and GSK may be referred to individually as a “Party” and collectively as the “Parties.” Reference is made to that certain Definitive Collaboration Agreement between GSK and VIR dated June 9, 2020 (the “Existing Collaboration Agreement”). This PCA sets forth the key terms upon which the Parties would expand the collaboration to include (a) an antibody program directed towards influenza, (b) functional genomics approaches to Respiratory Viral Diseases (as defined below), and (c) antibody programs directed towards additional pathogens, each, as further described below (collectively, the “Collaboration”). It is anticipated that following the PCA Execution Date, the Parties will enter into a definitive agreement to include more detailed term
AMENDMENT No. 3 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 6th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
WHEREAS, Licensor and Licensee entered into a certain Exclusive License Agreement, effective as of July 31, 2018, and as amended by Amendment No.1 dated May 17, 2019 and Amendment No.2 dated September 29, 2020 (the “Agreement”); and
May 4, 2021 Ann (Aine) M. Hanly VIA EMAIL Dear Aine,Letter Agreement • May 6th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
This letter agreement (the “Agreement”) sets forth the terms and conditions of your continued employment with Vir Biotechnology, Inc. (“VirBio” or the “Company”). This Agreement supersedes and replaces all prior written employment agreements, offer letters, or oral promises regarding the subject matter herein, including, but not limited to, your initial offer letter agreement with the Company dated February 18, 2021.
AMENDMENT NO. 1 TO THE PATENT LICENSE AGREEMENTPatent License Agreement • May 6th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to the Patent License Agreement (this “Amendment”) is entered into as of the 23rd day of February, 2021 (the “Amendment Effective Date”) by and between Vir Biotechnology, Inc., a Delaware corporation having a principal place of business at 499 Illinois St., San Francisco, CA 94158 (“VirBio”), and Xencor, Inc., a Delaware corporation having a principal place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (“Xencor”). VirBio and Xencor may each be referred to herein individually as a “Party” or collectively as the “Parties”.
AMENDMENT NO. 1 TO THE PATENT LICENSE AGREEMENTPatent License Agreement • May 6th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to the Patent License Agreement (this “Amendment”) is entered into as of the 23rd day of February, 2021 (the “Amendment Effective Date”) by and between Vir Biotechnology, Inc., a Delaware corporation having a principal place of business at 499 Illinois St., San Francisco, CA 94158 (“VirBio”), and Xencor, Inc., a Delaware corporation having a principal place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (“Xencor”). VirBio and Xencor may each be referred to herein individually as a “Party” or collectively as the “Parties”.
